JPWO2023282344A1 - - Google Patents

Info

Publication number
JPWO2023282344A1
JPWO2023282344A1 JP2022555690A JP2022555690A JPWO2023282344A1 JP WO2023282344 A1 JPWO2023282344 A1 JP WO2023282344A1 JP 2022555690 A JP2022555690 A JP 2022555690A JP 2022555690 A JP2022555690 A JP 2022555690A JP WO2023282344 A1 JPWO2023282344 A1 JP WO2023282344A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022555690A
Other versions
JPWO2023282344A5 (ja
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to JP2022178039A priority Critical patent/JP7471613B2/ja
Publication of JPWO2023282344A1 publication Critical patent/JPWO2023282344A1/ja
Publication of JPWO2023282344A5 publication Critical patent/JPWO2023282344A5/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/712Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7125Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/50Methods for regulating/modulating their activity
    • C12N2320/53Methods for regulating/modulating their activity reducing unwanted side-effects

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022555690A 2021-07-08 2022-07-08 Pending JPWO2023282344A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022178039A JP7471613B2 (ja) 2021-07-08 2022-11-07 腎毒性軽減剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021113495 2021-07-08
PCT/JP2022/027103 WO2023282344A1 (ja) 2021-07-08 2022-07-08 腎毒性軽減剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022178039A Division JP7471613B2 (ja) 2021-07-08 2022-11-07 腎毒性軽減剤

Publications (2)

Publication Number Publication Date
JPWO2023282344A1 true JPWO2023282344A1 (ja) 2023-01-12
JPWO2023282344A5 JPWO2023282344A5 (ja) 2023-09-19

Family

ID=84800740

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022555690A Pending JPWO2023282344A1 (ja) 2021-07-08 2022-07-08
JP2022178039A Active JP7471613B2 (ja) 2021-07-08 2022-11-07 腎毒性軽減剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022178039A Active JP7471613B2 (ja) 2021-07-08 2022-11-07 腎毒性軽減剤

Country Status (4)

Country Link
EP (1) EP4368176A1 (ja)
JP (2) JPWO2023282344A1 (ja)
TW (1) TW202308664A (ja)
WO (1) WO2023282344A1 (ja)

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0506830B1 (en) 1989-12-20 2005-12-14 Avi Biopharma, Inc. Uncharged morpholino-based polymers having phosphorous-containing chiral intersubunit linkages
EP1191714B1 (en) 2000-09-22 2003-01-29 Alcatel Alsthom Compagnie Generale D'electricite Method for monitoring an optical waveguide, monitoring system and monitoring unit for said method
EP1330520A2 (en) * 2000-11-02 2003-07-30 Inex Pharmaceuticals Corp. Therapeutic oligonucleotides of reduced toxicity
JP2006038608A (ja) 2004-07-27 2006-02-09 Tokyo Electric Power Co Inc:The 超音波検査装置及び方法
JP2006129594A (ja) 2004-10-28 2006-05-18 Hitachi Ltd 船舶用電気推進装置の制御方法及びその装置
AU2005306075A1 (en) * 2004-11-19 2006-05-26 Novosom Ag Improvements in or relating to pharmaceutical compositions for local administration
LT2024499T (lt) 2006-05-10 2018-02-26 Sarepta Therapeutics, Inc. Oligonukleotido analogai, turintys katijonines jungtis tarp subvienetų
CN1868456A (zh) * 2006-06-25 2006-11-29 沈阳药科大学 反义脱氧寡核苷酸isis23665脂质体制剂及制备方法
ES2694726T3 (es) 2007-06-29 2018-12-26 Sarepta Therapeutics, Inc. Conjugados peptídicos específicos de tejido y métodos
MX2010004955A (es) 2007-11-15 2010-06-30 Avi Biopharma Inc Metodo de sintesis de oligomeros de morfolina.
CA2930393C (en) 2007-12-04 2022-11-29 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
NZ599395A (en) 2008-07-18 2013-10-25 Oncogenex Technologies Inc Antisense formulation
JP6478632B2 (ja) 2011-05-05 2019-03-06 サレプタ セラピューティクス, インコーポレイテッド ペプチドオリゴヌクレオチドコンジュゲート
CN102989007B (zh) * 2011-06-29 2015-12-16 湖州市中心医院 大规模制备注射用中期因子反义寡核苷酸纳米脂质体的方法
KR20220045091A (ko) 2011-11-18 2022-04-12 알닐람 파마슈티칼스 인코포레이티드 트랜스티레틴(TTR) 관련 질병을 치료하기 위한 RNAi 제제, 조성 및 그의 사용방법
CN117721110A (zh) 2011-12-28 2024-03-19 日本新药株式会社 反义核酸
AU2014259759B2 (en) 2013-05-01 2020-06-18 Ionis Pharmaceuticals, Inc. Compositions and methods
DK3019200T3 (da) 2013-07-11 2022-06-20 Alnylam Pharmaceuticals Inc Oligonukleotid-ligand-konjugater og fremgangsmåde til fremstiling deraf
JP6519842B2 (ja) 2013-10-04 2019-05-29 国立大学法人神戸大学 福山型筋ジストロフィー治療用アンチセンス核酸
SG10201811729PA (en) 2013-12-12 2019-02-27 Life Technologies Corp Membrane-penetrating peptides to enhance transfection and compositions and methods for using same
WO2015105083A1 (ja) 2014-01-07 2015-07-16 塩野義製薬株式会社 アンチセンスオリゴヌクレオチド及び糖誘導体を含む二本鎖オリゴヌクレオチド
KR20240035901A (ko) 2015-05-19 2024-03-18 사렙타 쎄러퓨틱스 인코퍼레이티드 펩티드 올리고뉴클레오티드 콘주게이트
JPWO2017010575A1 (ja) 2015-07-16 2018-04-26 協和発酵キリン株式会社 β2GPI遺伝子発現抑制核酸複合体
LT3554554T (lt) 2016-12-19 2022-11-25 Sarepta Therapeutics, Inc. Egzoną praleidžiantys oligomero konjugatai nuo raumenų distrofijos
CA3047010A1 (en) 2016-12-19 2018-06-28 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
WO2018118599A1 (en) 2016-12-19 2018-06-28 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy

Also Published As

Publication number Publication date
EP4368176A1 (en) 2024-05-15
JP7471613B2 (ja) 2024-04-22
JP2023130288A (ja) 2023-09-20
TW202308664A (zh) 2023-03-01
WO2023282344A1 (ja) 2023-01-12

Similar Documents

Publication Publication Date Title
BR112023005462A2 (ja)
BR112023012656A2 (ja)
BR112021014123A2 (ja)
BR112022024743A2 (ja)
BR102021018859A2 (ja)
BR112022009896A2 (ja)
BR102021007058A2 (ja)
BR102020022030A2 (ja)
JPWO2023282345A1 (ja)
JPWO2023282344A1 (ja)
BR112023011738A2 (ja)
BR112023016292A2 (ja)
BR112023004146A2 (ja)
BR112023011539A2 (ja)
BR112023011610A2 (ja)
BR112023008976A2 (ja)
BR112023009656A2 (ja)
BR112023006729A2 (ja)
BR102021020147A2 (ja)
BR102021018926A2 (ja)
BR102021018167A2 (ja)
BR102021017576A2 (ja)
BR102021016837A2 (ja)
BR102021016200A2 (ja)
BR102021015220A2 (ja)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230627

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230627

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240521